In human melanoma cell lines that contain drug resistance genes and those that exhibited all genotypes, antagonism of TRPM2 led to significant dose-dependent decreases in growth and proliferation, as well as dose-dependent increases in cell death [71]. Here, TRPM2 is linked to melanoma.